Week In Review: BioAtla And Pfizer In $1 Billion Oncology Drug Deal

BioAtla's $1 billion payout, which includes Pfizer's rights to the CTLA4 antibodies, is a combination of up-front, regulatory and sales milestone payments plus tiered royalties on potential revenues.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.